Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants
- 28 August 2003
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 22 (36), 5667-5676
- https://doi.org/10.1038/sj.onc.1206724
Abstract
Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which probably confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the CD95 (Fas/APO-1) gene, encoding a death receptor implicated in a variety of apoptotic responses. Moderate (40–50%) downregulation of CD95 mRNA and surface protein expression by mutant p53 correlates with partial protection against CD95-dependent cell death. Excess mutant p53 represses the transcriptional activity of the CD95 promoter, with the extent of repression varying among different tumor-associated p53 mutants. Furthermore, mutant p53 protein binds the CD95 promoter in vitro, in a region distinct from the one implicated in tight interactions of the CD95 gene with wild-type p53. Hence, the CD95 promoter is likely to be a direct target for downregulation by mutant p53. This activity of mutant p53 may contribute to its gain of function effects in oncogenesis.Keywords
This publication has 48 references indexed in Scilit:
- Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancerOncogene, 2001
- Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1Journal of Biological Chemistry, 2001
- A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53‐null mammary epithelial cell mode.The FASEB Journal, 2000
- Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutantsOncogene, 1999
- Mutant p53 protein expression interferes with p53-independent apoptotic pathwaysOncogene, 1998
- Regulation ofp53downstream genesSeminars in Cancer Biology, 1998
- The Region 3′ to the Major Transcriptional Start Site of the MDR1 Downstream Promoter Mediates Activation by a Subset of Mutant P53 ProteinsBiochemical and Biophysical Research Communications, 1995
- Structural characteristics of CD40 ligand that determine biological functionSeminars in Immunology, 1994
- Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Genes & Development, 1994
- Different Tumor-Derived p53 Mutants Exhibit Distinct Biological ActivitiesScience, 1990